A combination of grape extract, green tea extract and L-carnitine improves high-fat diet-induced obesity, hyperlipidemia and non-alcoholic fatty liver disease in mice.

Kang, Jong Soon; Lee, Won Kyung; Yoon, Won Kee; Kim, Nayang; Park, Sang-Ki; Park, Hyoung Kook; Ly, Sun Yung; Han, Sang-Bae; Yun, Jieun; Lee, Chang Woo; Lee, Kiho; Lee, Ki Hoon; Park, Song-Kyu; Kim, Hwan Mook
Phytotherapy research : PTR
2011Dec ; 25 ( 12 ) :1789-95.
ÀúÀÚ »ó¼¼Á¤º¸
Kang, Jong Soon -
Lee, Won Kyung -
Yoon, Won Kee -
Kim, Nayang -
Park, Sang-Ki -
Park, Hyoung Kook -
Ly, Sun Yung -
Han, Sang-Bae -
Yun, Jieun -
Lee, Chang Woo -
Lee, Kiho -
Lee, Ki Hoon -
Park, Song-Kyu -
Kim, Hwan Mook -
ABSTRACT
To develop a therapeutic agent for obesity-related metabolic disorders, a mixture of dietary components was prepared, including grape extract, green tea extract and l-carnitine (RGTC), and its effects on obesity, hyperlipidemia and non-alcoholic fatty liver disease examined. The RGTC dramatically inhibited the high-fat diet (HFD)-induced increase in body weight and fat in C57BL/6 mice, whereas food consumption was not affected by RGTC treatment. The RGTC also concentration-dependently suppressed the HFD-induced increase in plasma lipids, such as low-density lipoprotein cholesterol and triglycerides. In addition, increases in liver weight and liver steatosis were returned to normal by RGTC treatment in HFD-fed C57BL/6 mice. The plasma levels of glutamic-oxaloacetic transaminase and glutamic-pyruvic transaminase were also significantly down-regulated by RGTC treatment. These results suggest that RGTC suppressed HFD-induced obesity, hyperlipidemia and non-alcoholic fatty liver disease, suggesting that RGTC supplementation might be a promising adjuvant therapy for the treatment of these metabolic disorders. CI - Copyright ??2011 John Wiley & Sons, Ltd.
grape extract, green tea extract, l‐carnitine, high‐fat diet, hyperlipidemia, fatty liver disease
MESH
Adipose Tissue/drug effects, Alanine Transaminase/blood, Animals, Aspartate Aminotransferases/blood, Body Weight/drug effects, Carnitine/*pharmacology, Diet, High-Fat, Fatty Liver/*drug therapy, Hyperlipidemias/*drug therapy, Leptin/blood, Lipids/blood, Male, Mice, Mice, Inbred C57BL, Non-alcoholic Fatty Liver Disease, Obesity/*drug therapy, Plant Extracts/*pharmacology, Tea/chemistry, Vitis/chemistry
¸µÅ©

ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
This report suggest that RGTC is beneficial for the treatment of obesity, hyperlipidemia and NAFLD and that RGTC treatment might be a promising adjuvant therapy for the management of these metabolic disorders.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
10.1002/ptr.3476.
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå